Resilient through FY20, recent correction presents a 'buying opportunity' for Frencken: RHB

Despite the recent tech sell-down, Frencken Group remains attractive with strong potential in its medical and semiconductor segments, says RHB Group Research analyst Jarick Seet. 

Seet is maintaining “buy” on the technology solutions company, with a target price of $1.52.

“On March 8, we hosted Frencken Group for a non-deal roadshow (NDR) and came away feeling more confident of our bullish call despite the recent tech sell-down. We estimate this is an opportunity to purchase shares at a more attractive level and remain positive on its growth this year,” writes Seet in a March 9 note.